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To the Editor: 
Hidradenitis suppurativa (HS) is an auto-inflammatory skin disease characterised by recurrent, chronic 8 
painful and pruritic inflammatory nodules, abscesses and sinus tracts in predominantly the axillary, 9 
inguinal and gluteal areas. A key element of the HS pathophysiology is occlusion of the follicular 10 
infundibulum and subsequent cyst formation, followed by rupture of the cyst inducing an intense 11 
inflammatory response.(1) Accordingly, identification of inflammatory markers is important for the 12 
clinical stratification of HS, and may help refining treatment choices. To date, no studies have 13 
investigated inflammatory protein levels in the serum/plasma and skin in parallel in a cohort of HS 14 
patients. Therefore, the primary aim of this study was to simultaneously detect important cytokines and 15 
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Blood and skin samples from 20 patients with a dermatologist-verified diagnosis of HS and 10 healthy 17 
controls (Supplement M1) were prospectively collected in the department of Dermatology of the 18 
Erasmus University Medical Center and Sint Franciscus Hospital in Rotterdam, The Netherlands. Skin 19 
samples of HS patients suffering of Hurley I to III disease severity were taken from actively inflamed, 20 
non-fluctuating, indurated, erythemous lesions or plaques recurring on fixed locations. The research 21 
protocol was approved by the local Institutional Review Board (reference MEC-2013-22 
337/NL45264.078.13). All participants provided written informed consent. 23 
Punch biopsies of 4 mm in diameter were obtained and immediately snap-frozen in liquid nitrogen. 24 
Venous blood was collected in vacuum EDTA tubes under sterile conditions, and after separation of 25 
the plasma samples were aliquoted and stored at -80
o 
Plasma protein concentrations were expressed as picogram (pg) per milliliter (mL), whereas skin 31 
protein levels were normalised for milligram (mg) tissue dry weight (pg/mg). In case a protein level was 32 
below the detection limit, the lowest limit of quantification (LLOQ) was used for further calculations. If 33 
more than 50% of the samples per analysed protein in either the HS or healthy control group had 34 
values below the LLOQ, values were substituted by two categories: detectable versus non-detectable, 35 
i.e. above or below the LLOQ, respectively. For the primary objective either the Mann Whitney U test 36 
or Fisher’s exact test was used to assess the null-hypothesis that there was no difference in the levels 37 
of individual markers between control and HS samples. Secondly, correlations between protein levels 38 
of plasma and lesional HS skin were calculated (Supplement M4). Statistical analyses were conducted 39 
using SPSS Statistics 24.0 (IBM Corporation, Armonk, NY). A two-sided p value below 0.05 was 40 
considered significant. This level was corrected by a false discovery rate using the Benjamini 41 
Hochberg test for multiple comparisons.   42 
Celsius until analysis. Samples were analysed 26 
using the Meso Scale Discovery (MSD) V-PLEX™ Human Cytokine 30-plex kit (K15054D; Meso Scale 27 
Discovery, Gaithersburg, MD) according to the manufacturers’ instructions (Supplement M2). 28 
Moreover, three chemokines, which have not previously been reported to be overexpressed in HS 29 
patients, were additionally analysed by immunohistochemistry (Supplement M3).  30 
In plasma, 20 of 30 (66.7%) analytes were detected. In the skin 25 of 26 (96.2%) proteins were 43 
detected, while four proteins (IL-4, IL-7, VEGF, GM-CSF) were not analysed because they have not 44 
been validated for skin-derived samples. In plasma, CCL-26 was detected significantly more often in 45 
HS patients (16 of 20) compared with healthy controls (2 of 10), p=0.004 (Table 1). Accordingly, the 46 
median CCL-26 level in HS patients was 24.9 pg/mL, interquartile range 19.1−37.0 (Fig. S1). In 47 
contrast, plasma CXCL-10 levels were significantly lower in HS patients, p=0.003. In lesional skin, IL-48 
16 (p<0.001), IL-17A (p<0.001), CXCL-8 (p=0.001), plus IL-8 HA (p=0.011), representing very high 49 
CXCL-8 concentrations, IL-12/23p40 (p=0.007), CCL-4 (p=0.011), CXCL-10 (p=0.011) showed higher 50 
levels in HS patients compared with healthy controls (Table 2, Fig. S2). The elevated CCL-4 and 51 
CXCL-10 protein levels in HS lesions were confirmed by immunohistochemistry (Fig. S3). A strong 52 
staining of CCL-26 was observed in lesional skin, despite the fact that CCL-26 protein was not 53 
detected in lesional HS skin by the MSD assay (Table 2, Fig. S3). Only weak correlations were 54 
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Chemokine CCL-26 (also known as eotaxin-3) is a newly identified inflammatory marker in HS 56 
patients. Significant elevation of this chemokine in the serum has previously been reported in atopic 57 
dermatitis and cutaneous T-cell lymphoma, which are characterised by the infiltration of eosinophils, 58 
basophils, and specific subpopulations of T cells (2, 3), and all, like HS (4), diseases characterised by 59 
high pruritus scores. Interestingly, CCL-26 was found in abundance in the HS infiltrate by 60 
immunohistochemistry, but was not detected in skin homogenates, possibly because CCL-26 is too 61 
strongly bound to its receptor on the many eosinophils present in the HS infiltrate.(4)   62 
The cutaneous upregulation of IL-16 and chemokines CCL-4 and CXCL-10 is not surprising because 63 
they are produced by many immune cells, and play a crucial role in the induction and modulation of 64 
immune responses during infection and inflammation.(5, 6) In addition, our results obtained in the skin 65 
confirm previous findings demonstrating overexpression of IL-17 pathway-associated cytokines and 66 
chemokines such as IL-17A, IL-23p40 and CXCL-8 in HS.(1) The importance of neutrophils in the HS 67 
pathogenesis is underlined by the increased levels of CXCL-8 that can be cleaved by neutrophil 68 
elastase to activate Th17 cells to produce bioactive IL-17.(7) Some previously published results, that 69 
showed significant upregulation of TNF-α, IL-1ß and IL-10 in (peri)lesional HS skin, could not be 70 
confirmed statistically.(8, 9) This can be explained by the different approaches as in our study biopsies 71 
were homogenised for in situ assessment, while van der Zee et al. and Kelly et al. cultured the skin 72 
biopsies for respectively 24 and 3 hours. This step of ex vivo culturing of skin samples allows for a 73 
prolonged production of cytokines that may lead to higher cytokine levels in the culture media. 74 
This study has several strengths including the in parallel assessment of inflammatory markers in skin 75 
and plasma using a sensitive and accurate detection technique. Limitations of this study are the limited 76 
sample size, which did not allow for a subgroup analysis by Hurley disease severity, and the use of a 77 
predefined panel of 30 cytokines and chemokines, which did not measure all previously reported HS-78 
biomarkers including antimicrobial peptides.  79 
In conclusion, CCL-26 is a newly identified inflammatory marker that is upregulated in the circulation of 80 
HS patients. Besides previously demonstrated overexpression of IL-17A, IL-23p40, CXCL-8 in HS 81 
lesions, this study found IL-16, CCL-4, CXCL-10 and CCL-26 as novel and potentially important 82 
players in the pathogenesis of HS. The local and systemic upregulation of CCL-26 in HS patients can 83 
be linked to the high pruritus score in HS. Furthermore, our results demonstrate that plasma gives a 84 
limited reflection of the activated local cutaneous inflammatory milieu. 85 
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TABLES 




Protein NN (n = 10) HS (n = 20) LLOQ 
Unadjusted 
p value 
 pg/mL median (IQR) or x/total median (IQR) or x/total pg/mL 
 
1 CXCL-10 (IP-10) 402.7 (328.7-550.5) 277.4 (236.0-328.8) 2.40 0.003*  
2 CCL-26 (Eotaxin-3) 2/10 16/20 18 0.0041*  
3 IL-12/23p40 132.7 (97.7-182.5) 104.0 (74.6-127.2) 1.30 0.055 
4 IL-1α 1.8 (1.7-3.6) 4.2 (2.4-10.2) 0.62 0.055 
5 CCL-4 (MIP-1β) 119.4 (66.6-176.0) 78.5 (59.9-102.5) 2.10 0.091 
6 TNF-β 2/10 0/20 0.28 0.103 
7 IL-1β 3/10 13/20 0.24 0.122 
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9 INF-γ 8.8 (5.3-14.0) 6.9 (4.8-8.9) 2.20 0.155 
10 IL-15 2.0 (1.7-2.3) 1.7 (1.5-2.1) 0.32 0.198 
11 IL-7 18.6 (14.8-24.2) 22.3 (17.0-30.3) 0.32 0.214 
12 IL-10 0.3 (0.2-0.4) 0.2 (0.2-0.3) 0.16 0.231 
13 CCL-3 (MIP-1α) 2/10 1/20 15.60 0.251 
14 CXCL-8 (IL-8) 8.7 (7.2-9.7) 7.1 (6.0-9.1) 3.80 0.286 
15 IL-16 208.0 (191.9-287.3) 257.9 (186.1-317.9) 4.20 0.475 
16 CCL-11 (Eotaxin-1) 135.9 (95.6-181.4) 151.6 (118.5-210.1) 5.60 0.502 
17 IL-6 1.3 (0.9-2.6) 1.1 (0.7-2.6) 0.36 0.530 
18 IL-13 1/10 1/20 0.98 0.532 
19 IL-17A 4/10 6/20 2.10 0.690 
20 CCL-17 (TARC) 385.8 (222.6-511.6) 325.9 (259.9-653.7) 2.80 0.713 
21 TNF-α 2.6 (2.3-3.2) 2.5 (2.2-3.0) 0.64 0.779 
22 CCL-13 (MCP-4) 188.0 (160.3-234.8) 210.6 (120.9-238.3) 4.80 0.880 
23 CCL-2 (MCP-1) 85.0 (75.3-99.1) 83.0 (62.9-114.9) 0.22 0.983 
24 VEGF 140.1 (116.0-200.0) 155.0 (103.6-250.7) 7 0.983 
25 IL-2 ND ND 0.68 - 
26 IL-4 ND ND 0.38 - 
27 IL-5 ND ND 0.40 - 
28 IL-12p70 ND ND 0.74 - 
29 GM-CSF ND ND 1.80 - 
30 IL-8 HA ND ND 344 - 
 
* Significant after correction with the Benjamini Hochberg test (p < 0.0042).  
HS: hidradenitis suppurativa patients. IQR: Interquartile Range. LLOQ: Lowest Level Of Quantification. x: number of samples 
with a detectable value. ND: Not Detected. NN: healthy controls. IL-8 HA (human antibody) has been validated for the MSD V-
PLEX™ kit, and is recommended when high CXCL/IL-8 levels are anticipated. 
 
 




Protein NN (n = 10) HS (n = 20) 
Unadjusted 
p value 
 pg/mg skin tissue median (IQR) or x/total median (IQR) or x/total  
1 IL-16 10.90 (7.67-13.09) 57.54 (38.50-120.81) <0.001* 
2 IL-17A 0/10 15/20 <0.001* 
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4 IL-12/23p40 0.10 (0.08-0.17) 0.25 (0.14-0.47) 0.007* 
5 CCL-4 (MIP-1β) 0.13 (0.08-0.15) 0.62 (0.19-1.83) 0.011* 
6 CXCL-10 (IP-10) 0.66 (0.18-1.10) 1.80 (1.07-3.32) 0.011* 
7 IL-8 HA 0/10 10/20 0.011* 
8 TNF-β 1/10 9/20 0.101 
9 CCL-3 (MIP-1α) 2/10 11/20 0.119 
10 INF-γ 3/10 13/20 0.122 
11 TNF-α 0/10 5/20 0.140 
12 IL-1β 0.13 (0.07-0.18) 0.21 (0.08-0.73) 0.155 
13 CCL-13 (MCP-4) 0.66 (0.53-0.72) 0.36 (0.25-0.66) 0.172 
14 IL-10 0.009 (0.005-0.011) 0.006 (0.004-0.008) 0.183 
15 CCL-17 (TARC) 2/10 9/20 0.246 
16 IL-5 0.024 (0.019-0.039) 0.017 (0.013-0.029) 0.322 
17 IL-1α 1.28 (0.92-2.10) 1.54 (0.86-4.40) 0.350 
18 IL-2 0.035 (0.016-0.081) 0.031-0.023-0.039) 0.530 
19 IL-6 0.26 (0.02-0.41) 0.08 (0.03-0.54) 0.530 
20 CCL-2 (MCP-1) 3.13 (0.30-4.82) 1.43 (0.42-3.35) 0.588 
21 IL-15 0.029 (0.026-0.039) 0.035 (0.026-0.045) 0.588 
22 CCL-11 (Eotaxin-1) 4/10 11/20 0.700 
23 CCL-22 (MDC) 1.80 (1.44-3.44) 1.82 (1.23-3.25) 0.983 
24 IL-13 0/10 1/20 1.000 
25 IL-12p70 3/10 6/20 1.000 
26 CCL-26 (Eotaxin-3) ND ND  - 
27 IL-7 NA NA  - 
28 VEGF NA NA  - 
29 IL-4 NA NA  - 
30 GM-CSF NA NA  - 
 
* Significant after correction with the Benjamini Hochberg test (p < 0.014).  
HS: hidradenitis suppurativa patients. IQR: Interquartile-e Range. LLOQ: Lowest Level Of Quantification. x: number of samples 
with a detectable value. ND: Not Detected. NA: Not Analyzed, not validated for skin samples. NN: healthy controls. IL-8 HA 
(human antibody) has been validated for the MSD V-PLEX™ kit, and is recommended when high CXCL/IL-8 levels are 
anticipated.  
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